Matthew Posard is a member of the Audit and Nominating and Corporate Governance Committees on the Halozyme board and also serves on the boards of DermTech, SlipChip Corporation and Omicia. Since February 2017, Mr. Posard has served as President and Chief Commercial Officer of GenePeaks, Inc., a computational genomics company. He was previously Executive Vice President, Chief Commercial Officer of Trovagene, Inc., where he oversaw sales, marketing, client services, market and business development until April 2016. Previously, Mr. Posard was Senior Vice President and General Manager of Illumina, Inc.’s New Emerging Opportunity Business, where he oversaw the development and transfer of Illumina technology into new markets. He joined Illumina in 2006 as Vice President of Global Marketing and served as Vice President of Global Sales from 2007 to 2011, leading Illumina’s successful commercial entry into the life science sequencing market. Prior to joining Illumina, Mr. Posard held various positions in strategic and product marketing at Gen-Probe, Inc., helping the company attain leading market positions in DNA probe-based infectious disease diagnostics and blood banking. Previously, he oversaw global marketing at Biosite, Inc., where he was instrumental in the successful introduction of the company’s BNP congestive heart failure biomarker and its BNP co-marketing collaboration with Beckman Coulter. Mr. Posard holds a B.A. degree in Quantitative Economics and Decision Science from the University of California, San Diego.